Recursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Advisors Asset Management Inc.

Key Points

• Advisors Asset Management Inc. significantly increased its stake in Recursion Pharmaceuticals by 753.8%, acquiring a total of 133,485 shares valued at approximately $706,000.
• Recursion Pharmaceuticals reported a quarterly revenue of $19.10 million, exceeding expectations, but posted earnings of (-$0.41) per share, missing the consensus estimate.
• Analysts' ratings for Recursion Pharmaceuticals include two "Buy" ratings and three "Hold" ratings, with a consensus target price of $7.25 per share.

Advisors Asset Management Inc. raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 753.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 133,485 shares of the company's stock after acquiring an additional 117,851 shares during the quarter. Advisors Asset Management Inc.'s holdings in Recursion Pharmaceuticals were worth $706,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. AlphaQuest LLC acquired a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $36,000. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 39.0% in the first quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after acquiring an additional 2,026 shares during the period. GF Fund Management CO. LTD. acquired a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $54,000. San Luis Wealth Advisors LLC acquired a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $54,000. Finally, ADG Wealth Management Group LLC acquired a new position in Recursion Pharmaceuticals in the first quarter valued at approximately $55,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Trading Up 1.7%

Shares of RXRX stock opened at $4.70 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.58 and a quick ratio of 3.58. The company has a market cap of $2.04 billion, a price-to-earnings ratio of -2.64 and a beta of 0.91. The stock has a 50 day simple moving average of $5.37 and a 200-day simple moving average of $5.38. Recursion Pharmaceuticals, Inc. has a 1-year low of $3.79 and a 1-year high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.06). The business had revenue of $19.10 million for the quarter, compared to analyst estimates of $15.38 million. Recursion Pharmaceuticals had a negative return on equity of 76.09% and a negative net margin of 1,004.91%.The company's quarterly revenue was up 33.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.40) earnings per share. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $5.52, for a total transaction of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares of the company's stock, valued at $3,688,447.44. This represents a 5.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 8.43% of the stock is currently owned by insiders.

Analysts Set New Price Targets

RXRX has been the subject of a number of analyst reports. Morgan Stanley initiated coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price target for the company. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Two analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus target price of $7.25.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.